AscellaHealth Taps New Leaders for Global Pharma Market Push

DUBLIN, Ireland – February 11, 2026 – AscellaHealth, a global solutions partner for the specialty pharmaceutical industry, today announced a significant expansion of its international operations, appointing veteran executives to spearhead its growth in Europe, the United Kingdom, and the Middle East. The move signals an aggressive strategy to streamline the notoriously complex journey from drug development to patient access for life sciences companies across the globe.

The promotions of Gillian Molloy to General Manager of International Operations and Alexis Moss to Vice President of Commercial for International Business place two seasoned leaders at the helm of this expansion. Based in Dublin and London respectively, Molloy and Moss will leverage their nearly four decades of combined experience to solidify AscellaHealth's position as a critical navigator in the high-stakes world of specialty pharmaceuticals.

“The promotions of Molloy and Moss enable AscellaHealth to further leverage their nearly four decades of combined experience across U.S. and European life sciences markets,” said Bill Oldham, Chairman and President of AscellaHealth, in a statement. “Their proven leadership continues to strengthen our ability to provide seamless support for both emerging and established biopharma companies as they navigate increasingly complex regulatory, distribution and commercialization pathways globally.”

Navigating a Labyrinthine Global Market

The challenge for biopharmaceutical companies is greater than ever. Bringing a novel therapy to market, particularly a specialty drug for a complex condition, involves navigating a labyrinth of disparate regulatory bodies, pricing pressures, and logistical hurdles. Research shows that even after a drug receives marketing authorization in the European Union, it can take an average of 531 days for it to become available to patients, a timeline that is steadily increasing.

In regions like the Middle East and North Africa, the landscape is even more fragmented, with varying patent laws and less transparent regulatory frameworks posing significant barriers to entry. AscellaHealth aims to position itself as the central nervous system for companies facing these challenges. Its integrated model combines international pharmaceutical distribution, licensed and unlicensed medicine supply, named patient programs, and clinical trial support under a single, cohesive strategy.

This end-to-end approach is designed to eliminate friction points that can delay or derail a product launch. By managing everything from regulatory submissions to last-mile delivery and patient support, the company offers a streamlined pathway through what is often a chaotic process.

“Life sciences companies are operating amid significant uncertainty, but also extraordinary opportunity,” stated Gillian Molloy, the newly appointed General Manager. “With over 20 years of experience in commercial strategy and payer engagement across the EU, UK and the Middle East, my focus is to help companies move seamlessly from early planning to successful commercialization, grounded in deep market insight and an unwavering commitment to the highest standards of patient care.”

A Strategic Consolidation for Market Dominance

AscellaHealth’s expansion is not merely about organic growth; it is a calculated move of strategic consolidation. The company is bolstering its capabilities through the deep integration of key partners, effectively building a powerhouse in the global specialty pharmaceutical services market. The integration of CHAPPER healthcare, a global wholesaler and distributor operating in over 70 countries, provides an established and robust logistical backbone for AscellaHealth’s ambitions.

Further strengthening its European presence is the alliance with EUROPACCESS, which enhances distribution capabilities across the UK and EU. Crucially, the company is also incorporating the expertise of its affiliate, Actum Pharma, a U.S.-based firm specializing in helping emerging biopharma companies overcome commercialization hurdles for novel therapies.

This consolidation comes as the demand for outsourced commercialization services skyrockets. The global Pharma Contract Commercialization Organization (CCO) market was valued at approximately $42.5 billion in 2024 and is projected to surge to $75 billion by 2034. AscellaHealth's strategy directly targets this burgeoning market, offering a compelling alternative to building massive internal commercialization teams, particularly for small and mid-sized biopharma firms.

“Leading AscellaHealth’s international initiatives, I’m focused on connecting commercial strategy, distribution and patient support to deliver measurable outcomes for our clients,” said Alexis Moss, the new Vice President of Commercial. “Drawing on extensive experience across pharmaceuticals, distribution and healthcare services, the alignment of global commercial strategy with AscellaHealth, CHAPPER healthcare and Actum Pharma’s capabilities will create new opportunities for life sciences companies while supporting patients in more than 70 countries.”

The Faces of Expansion: New Leadership, New Vision

At the core of this strategic push are the two leaders tasked with its execution. Gillian Molloy and Alexis Moss bring a wealth of experience from some of the biggest names in healthcare. Molloy’s career includes senior roles in commercial strategy and payer engagement at Novartis Oncology, AstraZeneca, and Baxter. Her deep understanding of both European and U.S. markets provides a crucial bridge for companies looking to expand their footprint.

Similarly, Alexis Moss has over two decades of experience in strategic leadership roles at Pfizer, AAH Pharmaceuticals, and Lloyds Pharmacy Clinical Home Care. Her background spans the pharmaceutical, wholesale distribution, and clinical homecare sectors, giving her a unique, holistic view of the patient journey from manufacturer to home.

Their combined expertise represents the human engine driving AscellaHealth’s integrated model. Their leadership is intended to ensure that the company’s vast network of services—from regulatory consulting to patient support programs—operates as a single, efficient machine dedicated to accelerating patient access to critical medicines.

Advancing the Industry Dialogue

Beyond their operational roles, Molloy and Moss are positioned as thought leaders set to shape the conversation around global healthcare's most pressing issues. Their upcoming speaking engagements at the Life Science Access Academy in March 2026—Molloy on the realities of gene therapy and Moss on the evolution of homecare within the UK’s National Health Service—underscore their commitment to advancing the industry.

These platforms provide an opportunity to share insights gained from the front lines of global market access, reinforcing their expertise and influence. This public-facing engagement highlights the company's dual focus on executing its strategic growth plan while actively contributing to the broader dialogue on improving healthcare delivery and patient outcomes worldwide.